MRP: ₹895
₹739
₹ 156 Off
(Incl. of all taxes)
Qty
Buying in bulk?
In stock
Deliver to
- 7-day returns
- Secure payment
- International shipping
- Carefully packed
Get this at ₹ 702Extra 5% OffAdd items worth ₹999 to the cart & get extra 5% off
Get this at ₹ 665Extra 10% OffAdd items worth ₹1499 to the cart & get extra 10% off
Book Summary
About the BooK: Cardiometabolic Medicine 2022
“Cardiometabolic Medicine 2022” is to curb the growing menace of cardiometabolic
diseases by disseminating the current preventing and therapeutic strategies to
improve the cardiometabolic outcomes. Most of the cardiometabolic diseases like
obesity, diabetes, hypertension, atherosclerotic, cardiovascular disease etc.
commonly co-exists and produces multiple co-morbidities which are beyond the
reach of a physician or single specialist to comprehensively evaluate and treat
them and therefore requires a cohesive effort of several specialties. Salient
Feature Dedicated section on atherosclerotic cardiovascular disease (ASCVD),
emerging drugs vericiguat and omecamtiv mecarbil, new approved weapons for heart
failure like sacubitril valsartan and SGLT2 inhibitors. Dedicated section with
focus on Obesity, Lipid
- ISBN-13
- 9789390616473
- Language
- English
- Binding
- Paper Back
- Publisher
- Evangel Publications
- Publishing Date
- 2022-02
- Total Pages
- 132
Cardiometabolic Medicine 2022
Frequently bought together
Total for 3 items₹865₹1035You save ₹170
Product Specifications
Book Summary
About the BooK: Cardiometabolic Medicine 2022
“Cardiometabolic Medicine 2022” is to curb the growing menace of cardiometabolic
diseases by disseminating the current preventing and therapeutic strategies to
improve the cardiometabolic outcomes. Most of the cardiometabolic diseases like
obesity, diabetes, hypertension, atherosclerotic, cardiovascular disease etc.
commonly co-exists and produces multiple co-morbidities which are beyond the
reach of a physician or single specialist to comprehensively evaluate and treat
them and therefore requires a cohesive effort of several specialties. Salient
Feature Dedicated section on atherosclerotic cardiovascular disease (ASCVD),
emerging drugs vericiguat and omecamtiv mecarbil, new approved weapons for heart
failure like sacubitril valsartan and SGLT2 inhibitors. Dedicated section with
focus on Obesity, Lipid
Book Specifications
- ISBN-13
- 9789390616473
- Language
- English
- Binding
- Paper Back
- Publisher
- Evangel Publications
- Publishing Date
- 2022-02
- Total Pages
- 132